Mark Hopman - 24 Jun 2026 Form 4 Insider Report for Beta Bionics, Inc. (BBNX)

Reporting relationship: Chief Commercial Officer
Issuer ticker: BBNX
Reported as of: 24 Jun 2026
Net transaction value: -$18,880
SEC form: 4
Accepted by SEC: 25 Jun 2026, 16:34:10 UTC
Prior SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen Feider, Attorney-in-Fact

Key filing fact

Mark Hopman filed Form 4 for Beta Bionics, Inc. (BBNX) on 25 Jun 2026.

Key facts

This page summarizes Mark Hopman's Form 4 filing for Beta Bionics, Inc. (BBNX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 25 Jun 2026, 16:34.

Change

Previous filing in this sequence was filed on 05 Jun 2026.
Current net transaction value: -$18,880.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002048497 Primary reporting owner

Hopman Mark

Relationship: Chief Commercial Officer
Address: C/O BETA BIONICS, INC., 11 HUGHES, IRVINE
Signature: /s/ Stephen Feider, Attorney-in-Fact
Signature date: 25 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBNX transaction

Common Stock

Sale

Transaction value: $18,880
Shares: -1,258
Change %: -0.96%
Price: $15.01
Shares after: 129,354
Date: 24 Jun 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025.

Footnote F2

The weighted average sale price for the transaction reported was $15.0083 and the range of prices were between $15.00 and $15.015. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.